For NCEs developed as therapeutic agents for major depressive disorder
Suven Life Sciences announced the grant of one (1) product patent from Eurasia (020506) and one (1) product patent from Israel (220229) corresponding to the New Chemical Entities (NCEs) for the treatment of disorders associated with Neurodegenerative diseases and these Patents are valid through 2029 and 2030 respectively.The granted claims of the patents include the class of selective alpha-4-beta-2 compounds discovered by Suven and are being developed as therapeutic agents for major depressive disorder (MDD).
With these new patents, Suven has a total of fourteen (14) granted patents from Eurasia and three (3) granted patents from Israel.
Powered by Capital Market - Live News
